Navigation Links
Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
Date:3/28/2011

SAN DIEGO, March 28, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data highlighting the burden of Clostridium difficile infection using National health insurance claims and survey databases will be presented on April 2, 2011 at the 21st Annual Scientific Meeting of The Society for Healthcare Epidemiology of America (SHEA).  

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)Poster Presentation Information:Title:

Rates of Recurrence and Mortality among Patients with a Diagnosis of Clostridium Difficile Infection in the United States: An Analysis Using National Health Insurance Claims and Survey DatabasesPresenter:

Erik R. Dubberke, MD, MSPH, Washington University School of Medicine, St. Louis, MODate:

Saturday, April 2, 2011 Time:

1:00 p.m. to 2:15 p.m. Central TimeLocation:

Hilton Anatole Hotel, Trinity Ballroom, Dallas, TexasPresentation #:

152About OptimerOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

ContactsOptimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
858-909-0736
Canale Communications, Inc.
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
2. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
3. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
4. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
5. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
6. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
7. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
8. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
10. Optimer Pharmaceuticals Announces Key Additions to Management Team
11. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2018)... ... 2018 , ... Daylight Detox & Recovery Center is giving back this holiday ... children countywide who are in the foster care system. Daylight not only works to ... local treatment centers. , “With all the media attention on local treatment centers not ...
(Date:12/5/2018)... ... 2018 , ... Trivellini Tech announces the latest version of Trivellini system ... known as Mamba Nano, Trivellini Long Hair introduces the ability to harvest long hair ... has the same capabilities as the last generation but it can also be programmed ...
(Date:12/5/2018)... Fla. (PRWEB) , ... December 05, 2018 , ... ... navigation and revenue cycle management announced the hiring of Dr. Tony Andrulonis, MBA ... a rapidly growing workforce of over 20,000 medical scribes and support staff. Prior ...
Breaking Medicine Technology:
(Date:12/5/2018)... ... December 05, 2018 , ... ... and Consulting services, announced its new office location in Paris, France during the ... of clinical trial operations in Europe and additional in-country personnel. , “The new ...
(Date:12/5/2018)... ... 05, 2018 , ... Northcentral University (NCU) has today announced the launch of ... on a weekly rolling basis to registered nurses, the Master of Science in ... will prepare degree candidates to become leaders in the high-demand field. , ...
(Date:12/5/2018)... (PRWEB) , ... December 05, 2018 , ... You can ... and LTRMN. , LTRMN , is a powerhouse in the cannabis industry with ... True Terpenes is an industry leading, award winning , botanical terpene ...
(Date:12/5/2018)... Mass. (PRWEB) , ... December 05, 2018 , ... ... intelligence, and analytics on the healthcare provider market, announced today that it was ... the 500 North American companies with the highest growth in the fields of ...
(Date:11/29/2018)... Fla. (PRWEB) , ... November ... ... study was published and released last month in the journal BMC Infectious ... check point bins are crawling with infectious viruses that can cause serious ...
Breaking Medicine News(10 mins):